1. Siavoshi F, Malekzadah R, Daneshmand M, Ashktorab H.
Helicobacter Pylori endemic and gastric disease. Dig Dis Sci.
2005;50: 2075-80
2. Yoshiko I, Koji S, Kentaro T, et al. Significant association between Helicobacter pylori infection and serum C-reactive protein. International Journal of Medical Science. 2008, 5, 224-29
3. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M.
Prospetive relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart 1996;75:568-72
4. Kowalski M, Pawlik M, Konturek J W, Knturek SJ. Helicobacter pylori in coronary artery disease. Journal of Physiology and Pharmacology 2006, 57, supp 3, 101-11.
5. Liliana S, France G, et al. Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systemic Review and Meta-analysis. Clinical Infection Diseases.
2004;39:206-17
6. Settin D, Waldmann A, Strohle A, Hahn A. Association between Helicobacter pyloti infection, C-reactive protein and status of B vitamins. Advances in Medical Sciences. Vol 53(2) 2008, 205-13
7. Al-Fawaeir S, Abu Zaid M. Serum levels of high sensitivity C-reactive protein (hs-CRP) in Helicobacter pylori infected patients. J Invest Biochem 2013;2(1):32-36
8. Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumo M, Kambe M. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am. Coll Cardiol. 2005 Apr 19;4(8):
1219-22
9. Minocha A. Handbook of Digestive Disease. Black Incorporated.
2004; 19-21
10. Talley NJ, Holtman G. Approach to the patient with dyspepsia and related functional gastrointestinal complaints. In: Yamada T, et al, ed. Principles of Clinical Gastroenterology. Blackwell.
2008; 38-61
11. Hunt RH, Fallone C, Zanten SV, Sherman P, Flook N, Smaill F, Thomson ABR. Etiology of Dyspepsia: Implications for Empirical Therapy. Can J Gastroenterol 2002;16(9):635-41
12. Jones RH, Lipleard S. Prevalence of symptoms of dyspepsia in the comunity. Br Med J 1989;298:30-2
13. Talley N, Zinsmeister A, Schexk C. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68
14. Wang VS, Burakoff R, functional (non ulcer) Dyspepsia. In:
Gastroenterology, hepatology & Endoscopy. McGraw-Hill, 2009.
189-99
15. Baker G, Fraser RJ, Young G. Subtypes of Functional Dyspepsia. World Journal of Gastroenterology, 2007. May 7;
12(17) 2667-71
16. Wong J. Dyspepsia. In: Wong JLH, Murray I, Hussaini SH, Dalton, HR, ed. Clinic Handbook Gastroenterology. 1st ed. Bios 2002;1-11
17. Lew E. Peptic Ulcer Disease. In: Greenberger NJ, Blumberg RS, Burakoff R, ed. Current Diagnosis & Treatment Gastroenterology, Hepatology & Endoscopy, McGraw-Hill. 2009.
175-83
18. Thompson AR, Barkun AN, Armstrong D, et al. The prevalence of clinical significant endoscpic findings in primary care patientswith uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther: 2003;17:1481-91
19. Tepes B. Subgroups of Dyspepsia. In: Duvnjak M, ed.
Dyspepsia in Clinical Practice. Springer Science, 2011. 9-18 20. Soll AH. Consensus conference. Medical treatment of peptic
ulcer disease. Practical guidelines. Practical Parameters of the American College of Gastroenterology. JAMA. 1996;275:622–9.
21. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia.
Gastroenterology. 1998;114:582–95.
22. Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol.
1998;10:27–32
23. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–79.
24. Tack J. Dyspepsia. In Feldman M, Friedman LS, Brandt LJ.
Sleisenger and Fordtran’s gastrointestinal and liver disease:
patophysiology/diagnosis management. 9th ed. Vol 1. Saunders Elsevier, 2010. 183-95
25. Baker G, Fraser RJ, Young G. Subtypes of functional dyspepsia. World J Gastroenterol 2006 May 7; 12(17): 2667-2671
26. Parsonnet J. Helicobacter pylori: the size of the problem. Gut 1998;43 (suppl 1):56-9
27. Dunn BE, Cohen H, Blaser MJ. Helicobacter Pylori. Clinical Microbiology Reviews, vol. 10, no. 4 Oct. 1997, 720-41
28. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori Infection. Clinical Microbiology Reviews, July 2006;449-90
29. Koskenpato J. Helicobacter pylori and Functional Dyspepsia.
Department of Medicine Tampere University Hospital, Finland.
Helsinki 2001
30. Parsonnet J. Helicobacter pylori: the size of the problem. Gut 1998;43 (suppl 1):56-9
31. Jenks PJ. Helicobacter spp. and Related Organisms in Principles and Practice of Clinical Bacteriology 2nd ed. John Wiley & Sons, Ltd 2006; 40:473-83
32. Redeen S. Chronic Gastritis Diagnosis, natural History and consequences. Linkoping University Medical Dissertation.
33. Chiba N. Ulcer Disease and Helicobacter pylori. In: Mc Donald, JW D, Burroughs AK, Feagan BG, ed. Evidence-based Gastroenterology and Child Health, 2nd ed. Blackwell. 2004:
82-116
34. Fleming SL. Deadly Diseases and Epidemics Helicobacter Pylori. Chelsea House Publishing. 2007.
35. Surbaum S, Michetti P. Medical Progress Helicobacter pylori Infection. NEJM Oct 10, 2002, vol. 347, no. 15
36. Marshall BJ, Gilman RH. Helicobacter Pylori Infection. In:
Guerrant RL, Walker DH, Weller PE, ed. Tropical Infectious Disease. Principles, Pathogens, & Practice. 2nd ed. Elsevier, Churchill Livingstone, 2004: 300-5
37. Rojas GC, Hiriart MM, Vidal YL. Helicobacter Pylori. Focus on CagA and VacA Major Virulence Factors. Salud publica de Mexico, 2004 vol. 46 No 6: 538-48
38. Glupzynski Y. Microbiological and serological diagnostic tests for Helicobacter pylori. An overview. British Medical Bulletin.
1998; 54(no.1) 175-86
39. Soll AD, Graham DY. Approach to the patient with dyspepsia and peptic ulcer disease. In: Yamada T, Alpers DH, kalloo AN, ed. Principles of Clinical Gastroenterology. 1st ed. Wiley Blackwell. 2008: 99-121
40. Andrews J, Marsden B, Brown D, et al. Comparison of three stool antigen tests for Helicobacter pylori detection. J. Clin.
Athol. 2003; 56: 769-71
41. Thomas R. screening for Helicobacter pylori. Rev. Port. Clin.
Geral. 2006; 22: 585-9
42. Yi-huil, Hong G, Peng-Bing Z,et al. Clinical Value of Helicobacter pylori stool antigen test, immunocard STAT HpSA, for detecting H. pylori infection. World J. Gastroenterology, March 2004 voll10, no 6: 913-4
43. Velozzi EM, Guigliano ER. The Genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology, 2 nd ed. Taylor & Francis 2009: 579-602
44. Velozzi EM, Guigliano ER. The genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology, 2nd ed. Taylor & Francis 2009: 579-602
45. Jialal I, Devaraj S. Modulation of Biomarkers of Inflammation. In:
Ballantyne CM, ed. Clinical Lipidology. A companion to Braunwald’s Heart Disease, 1st ed. Saunders Elsevier 2009:
396-404
46. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology and disease management. Humana press 2006: 229-34
47. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology and disease management. Humana press 2006: 229-34
48. Farraj M, Salem N. C-reactive protein. In Blood cell – An overview ofstudies in hematology. Intech open science.
2012;89-100
49. Baiber AR, Recinos III A, Eledrisi MS. Vascular inflammation as a cardiovascular risk factor. In: Runge MS, Patterson C, ed.
Principles of Molecular Cardiology. Humana press 2005: 577-604
50. Lonn ME, Smieja M, Yusuf S. Emerging approach in cardiovascular prevention. In: Yusuf S, Cairns JA, Camm AJ, et al, ed. Evidence-based Cardiology, 2nd ed: 219-30
51. Rifai N. High sensitifity C-Reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clinical chemistry 2005 . 51. No. 3: 504-5
52. Ridker PM, Hennekens CH, Buring JF, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEJM March 23 2000; 342:
no. 12. 836-43
53. CRPHS, cobas, 2011. 6.V6 Englis
54. One step H.pylori Antigen rapid tsest in human fecal specimen.
SD Bioline H.pylori Ag
55. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-Reactive protein levels as marker of bacterial infection: A systemic review and meta-analysis. CID 2004:39; 206-17
56. Andersen LP, Holck S, Janulaityte-Gunther D, et al.
Inflammatory markers and interleukin in patients with functional dyspepsia, with and without Helicobacter pylori infection. FEMS Immunology and Medical Microbiology 44 (2005) 233–238
57. Suat S, Bekir K, Mustafa A, et al. Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections? J Med Microbiol. 2004; 53:
639-44.
Lampiran 1
